Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 179

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 5
Chunk 179
---
 Biopharma business unit of €0.7 million in 2024, €0.8 million in 2023 and €2.0 million in 2022;
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investment in a new albumin purification and filling plant for bags of €20.2 million in 2024, €20.5 million in 2023 and €17.6 million in 2022; and
------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments for a new E2E supply chain system flow of €3.0 million in 2024, €2.8 million in 2023 and €0.6 million in 2022.
------------------------------------------------------------------------------------------------------------------------------
Quebec (Canada):

●   investments of €75.0 million in 2024, €44.8 million in 2023 and €56.9 million in 2022 to remodel Canada facility for fractionation increase, Albumin manufacturing and Gamunex addition.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
San Diego (California, United States):

●   investments of €0.2 million in 2024, €0.2 million in 2023 and €0.3 million in 2022 to expand manufacturing capacity for our NAT Diagnostic business, including quality control, research and development labs and an R&amp;D pilot plant; and
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments of €5.2 million in 2024, €4.7 million in 2023 and €6.8 million in 2022 to build a new immunohematology manufacturing facility in building 10895.
----------------------------------------------------------------------------------------------------------------------------------------------------------------
Emeryville (California, United States):

●   investments of €0.1 million in 2023 and €0.3 million in 2022, for the new protein manufacturing process and scale up labs based on mammalian cell cultures.
---------------------------------------------------------------------------------------------------------------------------------------------------------------
Other Investments. Other relevant capital projects relating to the expansion and improvement of our manufacturing facilities during 2024, 2023 and 2022 were:

●   investments in serialization to enhance manufacturing and packaging identification of €0.1 million in 2024, €0.5 million in 2023 and €1.3 million in 2022;
--------------------------------------------------------------------------------------------------------------------------------------------------------------

●   investments in new donor centers and donor center expansions in the United States of €5.0 million in 2024, €4.6 million in 2023 and €23.8 million in 2022;
--------------------------------------------------------------------------------------------------------------------------------------------------------------
115

●   investments of